Low vs higher dose target of rapamycin inhibitor (TOR‐ I): secondary outcomes
Biopsy‐proven acute rejection · primary immunosuppression in kidney transplant recipients
Low probably leads to higher biopsy‐proven acute rejection compared with higher dose target of rapamycin inhibitor (TOR‐I): primary outcomes (moderate certainty).
1 finding from 1 review
- Target of rapamycin inhibitors (TOR‐I; sirolimus and everolimus) for primary immunosuppression in kidney transplant… 2019 · Cochrane Headline outcomes onlyRR 1.26 [1.1, 1.43]11 studies · 3731 participantsModerate